Regeneron inks drug pricing deal with Trump, will offer new hearing-loss therapy for free
Summary
Regeneron is the latest in a string of major drugmakers to make pricing concessions for new and existing medicines under agreements with Trump.
Description
Regeneron is the latest in a string of major drugmakers to make pricing concessions for new and existing medicines under agreements with Trump.
Original reporting
AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.
Open original source